413573-66-7Relevant academic research and scientific papers
Discovery of Potent Inhibitors of Streptococcus mutans Biofilm with Antivirulence Activity
Nijampatnam, Bhavitavya,Ahirwar, Parmanand,Pukkanasut, Piyasuda,Womack, Holly,Casals, Luke,Zhang, Hua,Cai, Xia,Michalek, Suzanne M.,Wu, Hui,Velu, Sadanandan E.
, p. 48 - 55 (2021)
Dental caries is a bacterial infectious disease characterized by demineralization of the tooth enamel. Treatment of this disease with conventional antibiotics is largely ineffective as the cariogenic bacteria form tenacious biofilms that are resistant to such treatments. The main etiological agent for dental caries is the bacterium Streptococcus mutans. S. mutans readily forms biofilms on the tooth surface and rapidly produces lactic acid from dietary sucrose. Glucosyl transferases (Gtfs) secreted by S. mutans are mainly responsible for the production of exopolysaccharides that are crucial for the biofilm architecture. Thus, inhibiting S. mutans' Gtfs is an effective approach to develop selective biofilm inhibitors that do not affect the growth of oral commensals. Herein, we report a library of 90 analogs of the previously identified lead compound, G43, and exploration of its structure activity relationships (SAR). All compounds were evaluated for the inhibition of S. mutans biofilms and bacterial growth. Selected compounds from this library were further evaluated for enzyme inhibition against Gtfs using a zymogram assay and for growth inhibition against oral commensal bacterial species such as Streptococcus gordonii and Streptococcus sanguinis. This study has led to the discovery of several new biofilm inhibitors with enhanced potency and selectivity. One of the leads, IIIF1, showed marked reduction in buccal, sulcal, and proximal caries scores in a rat model of dental caries.
Identification of chemokine receptor CCR4 antagonist
Purandare, Ashok V.,Gao, Aiming,Wan, Honghe,Somerville, John,Burke, Christine,Seachord, Carrie,Vaccaro, Wayne,Wityak, John,Poss, Michael A.
, p. 2669 - 2672 (2007/10/03)
The present study reports the identification and hits to leads optimization of chemokine receptor CCR4 antagonists. Compound 12 is a high affinity, non-cytotoxic antagonist of CCR4 that blocks the functional activity mediated by the receptor.
